GlassScriptPhysician profile
Firas Kassab
NPI 1366649014
$79,916.97
in general payments reported to CMS, 2019-2025
45 companies · $9,808 in 2025
The $9,808 reported for 2025 was more than what 90% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,734 · 2020: $11K · 2021: $19K · 2022: $16K · 2023: $9,213 · 2024: $7,281 · 2025: $9,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $7,902 · Consulting Fee: $3,680 · Travel and Lodging: $2,800 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,800.00 |
| Food and Beverage | $7,901.82 |
| Consulting Fee | $3,680.00 |
| Travel and Lodging | $2,800.10 |
| Education | $119.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61,941.68 | 2019-2025 | Ofev, Cyltezo |
| Janssen Biotech, INC. | $4,242.38 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $3,652.73 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Ucb, INC. | $1,651.06 | 2019-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $1,539.77 | 2019-2023 | Krystexxa |
| Abbvie INC. | $1,128.25 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $801.26 | 2019-2025 | |
| Pfizer INC. | $757.40 | 2019-2025 | |
| Lilly USA, LLC | $605.63 | 2019-2025 | Taltz |
| Glaxosmithkline, LLC. | $432.15 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $418.46 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $318.12 | 2021-2025 | Saphnelo |
| Genentech USA, INC. | $290.27 | 2019-2025 | Actemra, Gazyva |
| Radius Health, INC. | $273.08 | 2019-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $205.59 | 2021-2025 | Strensiq |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Kassab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.